Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 202Central Nervous System Neoplasms 122Brain Neoplasms 107Gliosarcoma 85Glioma 68Astrocytoma 63Oligodendroglioma 34Neuroblastoma 29Medulloblastoma 20Neoplasm Metastasis 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 14Ependymoma 11Diffuse Intrinsic Pontine Glioma 11Breast Neoplasms 11Meningeal Carcinomatosis 8Neoplasms 7Lymphoma 7Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive 6Lymphoma, Follicular 6Head and Neck Neoplasms 6Esthesioneuroblastoma, Olfactory 6Burkitt Lymphoma 6Spinal Cord Neoplasms 5Salivary Gland Neoplasms 5Rhabdoid Tumor 5Recurrence 5

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1Neuropsychological Tests 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Control Groups 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infratentorial Neoplasms × Radiotherapy × CNS × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡